WO1998024792A1 - Glycosides anticoagulants et leurs compositions pharmaceutiques - Google Patents
Glycosides anticoagulants et leurs compositions pharmaceutiques Download PDFInfo
- Publication number
- WO1998024792A1 WO1998024792A1 PCT/HU1997/000078 HU9700078W WO9824792A1 WO 1998024792 A1 WO1998024792 A1 WO 1998024792A1 HU 9700078 W HU9700078 W HU 9700078W WO 9824792 A1 WO9824792 A1 WO 9824792A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- anhydro
- dithio
- mannopyranoside
- mixture
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 229930182470 glycoside Natural products 0.000 title description 16
- 150000002338 glycosides Chemical class 0.000 title description 15
- 239000003146 anticoagulant agent Substances 0.000 title description 5
- 229940127219 anticoagulant drug Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 65
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
- -1 nitro, cyano, amidino, aminothiocarbonyl Chemical group 0.000 claims abstract description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 16
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 7
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims abstract description 6
- 150000008191 D-altropyranosides Chemical class 0.000 claims abstract description 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims abstract description 4
- 150000007522 mineralic acids Chemical class 0.000 claims abstract description 4
- 150000007524 organic acids Chemical class 0.000 claims abstract description 4
- 239000002904 solvent Substances 0.000 claims description 29
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 15
- 239000003085 diluting agent Substances 0.000 claims description 4
- 150000008180 D-mannopyranosides Chemical class 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 125000003944 tolyl group Chemical group 0.000 claims description 3
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000002429 anti-coagulating effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- 239000000203 mixture Substances 0.000 description 49
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 38
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 36
- 125000003118 aryl group Chemical group 0.000 description 31
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 27
- 238000004440 column chromatography Methods 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 125000001841 imino group Chemical group [H]N=* 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 10
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- AXBVSRMHOPMXBA-UHFFFAOYSA-N 4-nitrothiophenol Chemical compound [O-][N+](=O)C1=CC=C(S)C=C1 AXBVSRMHOPMXBA-UHFFFAOYSA-N 0.000 description 8
- MVPUXVBBHWUOFS-UHFFFAOYSA-N 4-sulfanylbenzonitrile Chemical compound SC1=CC=C(C#N)C=C1 MVPUXVBBHWUOFS-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000002785 anti-thrombosis Effects 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001720 carbohydrates Chemical group 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 230000014508 negative regulation of coagulation Effects 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 3
- LVFZTPIRDLQIGF-KXNHARMFSA-N 4-[(2s,3r,4s,5s)-3,4,5-trihydroxythian-2-yl]sulfanylbenzonitrile Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CS[C@H]1SC1=CC=C(C#N)C=C1 LVFZTPIRDLQIGF-KXNHARMFSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229930182475 S-glycoside Natural products 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- LKFCPWBGBPJDRC-UHFFFAOYSA-M potassium;thiobenzate Chemical compound [K+].[O-]C(=S)C1=CC=CC=C1 LKFCPWBGBPJDRC-UHFFFAOYSA-M 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 150000003569 thioglycosides Chemical class 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000985710 Antennarius striatus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700043492 SprD Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- ADLJEAHDCMGZSZ-UHFFFAOYSA-N acetic acid;ethyl acetate;pyridine;hydrate Chemical compound O.CC(O)=O.CCOC(C)=O.C1=CC=NC=C1 ADLJEAHDCMGZSZ-UHFFFAOYSA-N 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229950002852 beciparcil Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 1
- UIJGNTRUPZPVNG-UHFFFAOYSA-N benzenecarbothioic s-acid Chemical compound SC(=O)C1=CC=CC=C1 UIJGNTRUPZPVNG-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940068911 chloride hexahydrate Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- QTDBPWPSHBVVMQ-UHFFFAOYSA-N ethyl acetate;tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl.CCOC(C)=O QTDBPWPSHBVVMQ-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- VOAPTKOANCCNFV-UHFFFAOYSA-N hexahydrate;hydrochloride Chemical compound O.O.O.O.O.O.Cl VOAPTKOANCCNFV-UHFFFAOYSA-N 0.000 description 1
- 150000002401 hexose derivatives Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002703 mannose derivatives Chemical class 0.000 description 1
- 150000008146 mannosides Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- UJQMLHKSZKBMMO-UHFFFAOYSA-N n,n-diethylethanamine;pyridine Chemical compound C1=CC=NC=C1.CCN(CC)CC UJQMLHKSZKBMMO-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 150000002971 pentose derivatives Chemical class 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 238000002328 two-dimensional heteronuclear correlation spectroscopy Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
Definitions
- This invention relates to novel 2,6-anhydro-1 ,2-dithio-pyranosides of the formula (I), more particularly to D-manno- and D-altropyranosides of formula (la-Id)
- R ⁇ represents a hydroxy or an azido group
- the compounds of the invention possess valuable pharmaceutical properties, especially anticoagulant activity, even when administered by the oral route.
- the aim of the invention was to synthesize such new carbohydrate derivatives which are stronger inhibitors of the coagulation process than the known ones and are orally active too.
- the compounds of the invention can be synthesized by different known methods.
- represents a hydroxy group and R2 represents a cyano group, can be prepared e.g. by treatment of an anomeric mixture of glycosides of formula (III),
- the above reaction can preferably be carried out by hydrolyzing the anomeric mixture of glycosides of formula (III) by using sodium methoxide in methanolic solution, and separating the obtained a, b-anomers (la and lb) by crystallization and/or column chromatography.
- glycosides of formula (III), which are new compounds, can be prepared e.g. by acetylating the known [I.I. Cubero et al.: Carbohydr. Res., 242,
- glycosides of formula (III) can preferably be carried out by using sulfuric acid in acetic anhydride for the methoxy acetoxy exchange reaction, and trimethylsilyl triflate as promoter for the condensation with 4- cyanothiophenol.
- represents a hydroxy group and R2 represents an aminothiocarbonyl group, can be prepared e.g. by treatment of a compound of formula (lb), wherein the meaning of R-j is as defined above and R2 is a cyano group, with hydrogen sulfide using an organic base as solvent.
- the above reaction can preferably be carried out, using acetone as solvent and methyl iodide as reagent at reflux temperature.
- the above reaction can preferably be carried out, using methanol or ethanol as solvent at reflux temperature.
- the above reaction sequence can preferably be carried out by using ethanol as solvent and sodium borohydride - nickel(ll) chloride as reagent for the reduction, pyridine as a base for the acetylation and sodium methoxide in methanol for removing the ester groups.
- the above reaction sequence can preferably be carried out by using sodium methoxide in methanolic solution for the hydrolysis of the anomeric mixture of glycosides of formula (VI), and separating the so obtained a, b-anomers (lc and Id) by crystallization and/or column chromatography.
- glycosides of formula (VI), which are new compounds, can be prepared e.g. by reacting the known [K. Toshima et al.: Tetrahedr. Lett., 33, 1491 (1992)] triacetate of formula (VII)
- glycosides of formula (VI) can preferably be carried out at low temperature, preferably at 0 °C, using trimethylsilyl triflate as promoter.
- the compounds of formula (la and lb), in which R-j represents an azido group and R2 represents a nitro group, can be prepared e.g. by reacting the diacetate of formula (VIII) with 4-nitrothiophenol in the presence of a promoter, removing the acetyl groups of the obtained anomeric glycosides in a lower aliphatic alcohol by treatment with base, and optionally separating the anomers.
- the above reaction sequence can preferably be carried out by reacting the diacetate of formula (VIII) with 4-nitrothiophenol in dichloromethane at low temperature, preferably at 0 °C, using trimethylsilyl triflate as promoter, or in 1 ,2-dichloroethane at 20 °C, using boron trifluorid etherate as promoter, hydrolyzing the obtained anomeric glycosides by sodium methoxide in methanol, and optionally separating the obtained a, b-anomers by crystallization and/or column chromatography.
- the compounds of formula (I) of the invention possess valuable anticoagulant activity.
- the compounds of the present invention as well as their pharmaceutically acceptable salts can be used as such or suitably in the form of pharmaceutical compositions. These compositions also fall within the scope of the present invention.
- compositions contain an amount required to excert the therapeutical effect of a compound of formula (I) or its pharmaceutically acceptable salt, in admixture with known carriers, excipients, diluents and/or other additives commonly used in the pharmaceutical practice.
- the antithrombotic compound is formulated in capsules or tablets which may contain excipients such as binders, lubricants, disintegration agents and the like.
- the antithrombotic compound is formulated in a pharmaceutically acceptable diluent, e.g. physiological saline (0.9 %), 5% dextrose, Ringer's solution and the like.
- the doses required to excert the therapeutical effect of the compounds according to the invention may be varied depending on the individual condition and age of the patient to be treated and finally these doses are determined by the attending physician. However, for the prevention and/or treatment of diseases, where the application of an anticoagulant is desirable, daily doses of these compounds falling between about 0.01 mg/kg of body weight and about 100 mg/kg of body weight and preferably between about 0.1 mg/kg of body weight and about 10 mg/kg of body weight are used by the oral or parenteral, e.g. intravenous, route.
- the compounds according to the invention and the process for the preparation thereof are illustrated in detail by the following not limiting Examples.
- Multiplicities of the 1 3 C NMR spectra were obtained from DEPT experiments. The assignment of the protons were based on homonuclear decoupling and DNOE experiments. Connectivities between identified protons and protonated carbons were determined by HETCOR experiments. MS spectra were recorded with a Finnigan MAT 8430 mass spectrometer. In the case of FAB spectra samples were dissolved in 3-nitrobenzaldehyde or in glycerin.
- the starting anomeric mixture of formula (III) can be prepared the following way:
- the starting compound of formula (VIII) can be prepared the following way:
Abstract
Cette invention concerne de nouveaux 2,6-anhydro-1,2-dithio-D-manno- et D-altropyrannosides de la formule (I) dans laquelle R1 représente un groupe hydroxy ou un groupe azido, R2 représente un groupe nitro, cyano, amidino, aminothiocarbonyle, -C(=NH)-OCH3, -C(=NH)-NH-NH2, -C(=NH)-SCH3 ou un groupe acétamido, ainsi que leurs sels d'addition d'acide formés avec des acides organiques ou inorganiques, si possible, ainsi que des compositions pharmaceutiques les contenant. Les composés de l'invention présentent des propriétés thérapeutiques, notamment anticoagulantes avantageuses.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU50646/98A AU5064698A (en) | 1996-12-04 | 1997-12-01 | Anticoagulant glycosides and pharmaceutical compositions thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU9603341A HUP9603341A3 (en) | 1996-12-04 | 1996-12-04 | Glucosides as blood-clotting-inhibitors and pharmaceutical compositions containing them |
HUP9603341 | 1996-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998024792A1 true WO1998024792A1 (fr) | 1998-06-11 |
Family
ID=89994513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU1997/000078 WO1998024792A1 (fr) | 1996-12-04 | 1997-12-01 | Glycosides anticoagulants et leurs compositions pharmaceutiques |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5064698A (fr) |
HU (1) | HUP9603341A3 (fr) |
WO (1) | WO1998024792A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0290321A1 (fr) * | 1987-05-04 | 1988-11-09 | Fournier Industrie Et Sante | Nouveaux beta-D-phényl-thioxylosides, leur procédé de préparation et leur application en thérapeutique |
EP0365397A2 (fr) * | 1988-10-18 | 1990-04-25 | Fournier Industrie Et Sante | Nouveaux beta-D-phényl-thioxylosides, leur procédé de préparation et leur utilisation en thérapeutique |
WO1995005182A1 (fr) * | 1993-08-13 | 1995-02-23 | Glycomed Incorporated | Oligosaccharides pontes et leurs derives sulfates |
-
1996
- 1996-12-04 HU HU9603341A patent/HUP9603341A3/hu unknown
-
1997
- 1997-12-01 WO PCT/HU1997/000078 patent/WO1998024792A1/fr active Application Filing
- 1997-12-01 AU AU50646/98A patent/AU5064698A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0290321A1 (fr) * | 1987-05-04 | 1988-11-09 | Fournier Industrie Et Sante | Nouveaux beta-D-phényl-thioxylosides, leur procédé de préparation et leur application en thérapeutique |
EP0365397A2 (fr) * | 1988-10-18 | 1990-04-25 | Fournier Industrie Et Sante | Nouveaux beta-D-phényl-thioxylosides, leur procédé de préparation et leur utilisation en thérapeutique |
WO1995005182A1 (fr) * | 1993-08-13 | 1995-02-23 | Glycomed Incorporated | Oligosaccharides pontes et leurs derives sulfates |
Non-Patent Citations (3)
Title |
---|
F BELLAMY ET AL: "Thioxyloside derivatives as orally active venous antithrombotics", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 30, 1995, pages 101 - 115, XP002056034 * |
K TOSHIMA: "The use of 2,6-anhydro-2-thio sugar for a highly stereocontrolled glycosylation", TETRAHEDRON LETTERS, vol. 31, no. 23, 1990, pages 3339 - 3342, XP002056035 * |
MASSON P J ET AL: "The effect of the.beta.-D-xyloside naroparcil on circulating plasma glycosaminoglycans. An explanation for its known antithrombotic activity in the rabbit", J. BIOL. CHEM. (JBCHA3,00219258);95; VOL.270 (6); PP.2662-8, LABORATOIRES FOURNIER S.C.A.;CENTRE DE RECHERCHE ET DEVELOPPEMENT; DAIX; 21121; FR. (FR), XP002056036 * |
Also Published As
Publication number | Publication date |
---|---|
HUP9603341A2 (hu) | 1998-10-28 |
AU5064698A (en) | 1998-06-29 |
HU9603341D0 (en) | 1997-01-28 |
HUP9603341A3 (en) | 1999-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jacquinet et al. | Synthesis of heparin fragments. A chemical synthesis of the trisaccharide O-(2-deoxy-2-sulfamido-3, 6-di-O-sulfo-α-D-glucopyranosyl)-(1→ 4)-O-(2-O-sulfo-α-L-idopyranosyluronic acid)-(1→ 4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose heptasodium salt | |
ES2423888T3 (es) | Pentasacáridos de heparina sintéticos | |
EP1489090A1 (fr) | Nouveaux dérivés de la pseudoérythromycine | |
EP0587364A1 (fr) | Procédé pour l'anomérisation des nucléosides | |
EP3415522A1 (fr) | Nouvel inhibiteur hybride de galactoside de galectines | |
EP3819302B1 (fr) | Oligosaccharide de sulfate de chondroïtine fucosylé, procédé de préparation correspondant, composition et utilisation associées | |
HU215152B (hu) | Eljárás pentaszacharid egységet tartalmazó szénhidrátszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására | |
JP4364959B2 (ja) | 炭水化物誘導体 | |
JP3594990B2 (ja) | 3−デオキシオリゴ糖、その製造方法およびそれを含有する医薬組成物 | |
US5332756A (en) | 3-deoxy-mannosamine derivatives | |
US3781267A (en) | O-esters of monosaccharides having ether groupings | |
Van Boom et al. | Synthesis of a Conformationally Constrained Heparin‐like Pentasaccharide | |
US6680304B2 (en) | Disaccharides with anti-arthrosic properties | |
Juetten et al. | Stereoselective. alpha.-glycosylation of nitro sugar evernitrose: synthesis of the terminal AB unit of everninomicin antibiotics | |
EP0907656A1 (fr) | Nouveaux glycosides anticoagulants et compositions pharmaceutiques les contenant | |
US4891425A (en) | N-glycosylamide derivatives, processes for their preparation and their use as medicaments | |
WO1998024792A1 (fr) | Glycosides anticoagulants et leurs compositions pharmaceutiques | |
WO1999028312A1 (fr) | Nouveaux glycosides anticoagulants et leurs compositions pharmaceutiques | |
US4220643A (en) | Nitrosourea pentose compounds | |
EP2857411B1 (fr) | Procédé de préparation de pentasaccharide d'héparine offrant une protection complète et son intermédiaire | |
US3664998A (en) | Process for converting peracylated cis-glycosy halides to peracylated trans-glycosyl halides and novel compounds | |
Kaluza et al. | Potential Anti-HIV Active Pyranoid Analogs of AZT | |
ES2202212T3 (es) | Benzofenona-a-d.glicopiranosidos, preparacion y uso terapeutico. | |
EP2721044B1 (fr) | Pentasaccharides synthétiques ayant une demi-vie courte et une activité élevée | |
CA2350755A1 (fr) | Benzylglycosylamides utilises comme inhibiteurs de la proliferation cellulaire des muscles lisses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |